United Health Products, Inc. develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. The company’s lead product, CelluSTAT, is derived from chemically treated cellulose obtained from cotton and is designed to absorb exudate from superficial wounds while helping to control bleeding. CelluSTAT expands upon contact with blood, forming a translucent gel that later breaks down into cellulose and salts, thereby avoiding…
United Health Products, Inc. develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. The company’s lead product, CelluSTAT, is derived from chemically treated cellulose obtained from cotton and is designed to absorb exudate from superficial wounds while helping to control bleeding. CelluSTAT expands upon contact with blood, forming a translucent gel that later breaks down into cellulose and salts, thereby avoiding interference with tissue healing. The product has received FDA 510(k) clearance for superficial use and the company is currently seeking premarket approval for its use in Class III human surgical procedures.
Revenue is generated primarily from the sale of CelluSTAT hemostatic gauze for superficial wound care applications, which includes sales to hospitals, clinics, and other point of care providers. Although the company has paused broader commercial activities to concentrate on obtaining FDA Class III approval, it continues to fulfill existing orders under its 510(k) clearance. In addition, United Health Products, Inc. has secured financing arrangements, such as the senior convertible promissory note with Alumni Capital LP, which provided net proceeds of $250,000 and includes an option to sell up to $4,000,000 of common stock through an Any Market Purchase Agreement. These funds support ongoing regulatory efforts, clinical studies, and operational expenses while the company pursues its PMA strategy.
United Health Products, Inc. competes in a market dominated by large established firms such as Baxter International, Becton Dickinson & Company, Johnson & Johnson (Ethicon), Teleflex, and 3M Company, and differentiates itself through its patented, chemical free, hypoallergenic hemostatic gauze that degrades to non toxic end products. The company’s technology avoids the use of thrombin, collagen, or animal derived components, which reduces the risk of adverse immune reactions. While larger competitors benefit from greater capital and broader product portfolios, United Health Products, Inc. focuses on a niche hemostatic agent that can be integrated into various surgical and trauma settings. Ongoing discussions with potential corporate partners aim to leverage external expertise for clinical development and commercialization once regulatory clearance is obtained.
The company serves hospitals, surgery centers, clinics, physicians, emergency medical services, fire departments, military medical providers, hemodialysis centers, nursing homes, assisted living facilities, dental and oral maxillofacial surgery offices, and veterinary hospitals. In anticipation of receiving Class III premarket approval, United Health Products, Inc. expects to expand its customer base to include academic medical centers, specialty surgical suites, and additional government health agencies. The diverse range of potential customers reflects the broad applicability of its hemostatic gauze across both external wound care and internal surgical environments. By maintaining a flexible manufacturing model through contract producers, the company can scale production in response to demand from these end users.